A051902, NCT04803201: Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma |
|
|
| Recruiting | 2 | 170 | US | Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral azacitidine | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma with TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified | 06/25 | 01/26 | | |
NCT04284228: Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT |
|
|
| Active, not recruiting | 1/2 | 22 | US | Infusion of NEXI-001 T Cells | NexImmune Inc. | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | 10/24 | 03/25 | | |
NCT04673617: AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 1/2 | 108 | US | AB-101, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, Bendamustine | Artiva Biotherapeutics, Inc. | Non Hodgkin Lymphoma | 11/24 | 11/24 | | |
realMIND, NCT04981795: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL |
|
|
| Recruiting | N/A | 100 | US | Tafasitamab | Incyte Corporation, Iqvia Pty Ltd | Diffuse Large B-cell Lymphoma | 10/25 | 08/26 | | |
